1

-, , ,
X , ,
,
, ,
.
.
, ,
, ,
, , ,
. ,
, ,
- ,
, .
.
,
.
(drug-drug interactions), (drug-food interactions)
, . (Russell, Pharmacotherapy).
,
,
.
.
, . , ,
, , , ,
, ,
, / .
, ,
, .
,
,
.
(drug-drug interaction), ,
,
, .
,
(- ,
). ,
: 1)
(antagonism), 2) (synergism), 3)
(summation), 4) (potentiation) 5) - (unexpected) .
,
( ..). ,
,
, (1+1=0). ,
,
.

2
(1+1=3).
, ,
(1+1=2). ,
- -
(1+0=2). - , ,
, .

, , ,
, ( ), ,
.
.
, , ,
,
.
, ,
.
, , 10-20% , . 8% ,
. ,
1-4% . 3
5% 20%,
10-20 . , 6 ,
, .
, , 6% ,
. , ,
2 6%, 50% 5
100% ( ) 8 .
, , ( , ),
, , .. , , , , ,
.
, ,
, . , 70%
, .
, .
, , ,
, , , .
40% 60 ,
80% , .
, , , , , 82%
.

3

, ,
, , .
, ,
, . ,
: , , ,
, .
, ,
, : ,
, , , .
1:


,

.
, , ,
. , ,
, ,
.
, , ,
, , , , Alzheimer .
,
, , ,
. . ,
,
, ( ),
.

4
2:
-

3:
40-50%

: , ,
82%

4:
-

, ,

. , , ,
, ,
. ,
( ),
, ,
, .
, ,
, , , .

, ,
.

5
,
, ,
, .

.
,
,
.
, , :
,
. ,
1 5 ( 5).

5:

1
2
3
4
5

, ,

, ,

, ,

,

, (1),
, ,
.
,
, per
os . (2),
,
.
, ,

. (3),
.
(4),
,
, . (5)
.

6

, , . , , , , , .
L-dopa carbidopa Parkinson,
. , ,
. , , ,
, .
, , . ,
- ,
. ,
,
.
( -)
, . ,
- , , ,
.

,
, .
:

: ,

per os: ,

K : ,

: -, ,

: ,

: ,

: , per os

: ,

, . .

.
, , ,
, . , ,
, , , .

7
6:
1

()

: ,

()

grapefruit

Torsades de pointes
(
)

grapefruit

- s

1,

, Mg

Torsades de pointes
(
)

()

,
1,
2.

grapefruit

()

2-

1,
:

grapefruit

(..
)

8

, , ,
, , .
, in vivo ( )

. ,
, in vitro ( ),
in vivo , , ,
( 1).

1: ,
.

9
.

in vitro, in vivo. ,
, ,
. ,
.
, ,
. in vitro
, . n vivo,
. ,
2 . ,
, .
.
,
, . PAS ,
, PAS
,
. , (8-12 ).
.
,
, . ,
, , .
)
,
. , ,
/ ,
. pH
, ,
( 1).
, , ,
Ca2+ (Al3+, Mg2+, Fe2+, Zn2+),
,
.
. ,
80%.
, ,
: ) pH , ) (
) ) ,
. ,
2-3 , .
, ,
, : ,

10
, ,
, 2-.
)
, ,
.
, ,
, , /
.
(, , , , , ,
, ..), (>90%)
. ,
, ,
. , ,
.
)
()
,
() .
.
450,
, 30 . : CYP3A4, CYP2D6, CYP1A2
.. . ,
, ,
, (). ,
, ,
grapefruit.
, ,
,
, .
,
, .

. ,
,
. , ,
,
.
)
, ,
.
,
. ,
,
. ,

11
, : - , PAS, ,
.
, pH ,
, ,
. ,
, . , pH
(,
), .
,
, ().
, , ,
, , ,
. ,
, .
,
,
.
.
, , , ,
, . )
, ) )
.
, .
, - ( 7).
, , ,
.
, -
. , , ,
, . ,
( 8).
, ,
( 9). ,
.

, .

12

7: ,

( & ),
,
, ,

,
,
,

,

QT
() +

s +

SSRIs

(, , , , ,
, , , )

() +

s

-

()

,
,

8:
( )

()

+
NaCl

+
NaCl

13

9: ,

per
os

L-dopa

per os

-

. ,
.

.
(, , , , , , ..),
. , ,
, , , ,
.
, , , , : ( ), (, AIDS). , L-dopa, Parkinson. , ,
( ) , (, - chianti - , , , ..),
, .
, -
().

14
, ,
.
grapefruit, , ,
.
, , , (,
, ),
grapefruit, .
,
, ,
. - , , (), ()
(), ,
-.
, ,

. , , -,
, ,
. , , () (, ), NaCl,
, , .
, , , , ,
(Coca-cola), ,
. , K, , , , , , .
, ( ,
) . ,
. , , ,
, .

-
, ,
( 10).
,
, , , 2-3 . , ,
.

15

10:

(2)*
-- (2)
(2)

(2)
(2)
(2)
per os (1)
(2)
per os (3)
(,
)
(, )
(, )

(, )
(1 2)

( )

.
,

(, ,
, )

(2)
-

(2 3)

, , ,
,
. , , , ,
, , ,
,
( ).
, , ,
.
( 20-30% , ),
, .

16
, , ,
. , ,
. ,
, , , , , d-, ,
40-50%.
. , ,
, .
, , 2-,
. , , , ,
, . , ,
, , ,
.

, ,
(, ..),
. , ,
,
, .
, . , .
, (
, ), , ,
, , , .
, , .
.
, per os
, , .
,
, . , ,
, , ,
, .
IV.
,
, (, , , , , , ,
, ..). ,
, ,
. ,
, , , , , ,
, .

17

, , ,
, . ,
,
. ,
. , , .

- - . ,
, . , , , , ,
, :

( , , ,
)

,

,

, , , :
, ,
,
,
, ,
, ,
, ,
, .
, ,
, .

1.
2.
3.
4.
5.
6.

Adverse drug interactions in dental practice, JADA, vol.130, January 1999, p.47-54
Cadicux R.J.: Drug interactions in the elderly. How multiple drug use increases risk
exponentially. Postgraduate Medicine, 86: 179, 1989.
- .
, 1994
Drug Interaction Facts. Ed. D.S. Tatro, Facts and Comparisons, St Louis, A Wolters Kluwer
Company, 2004
Evaluations of Drug Interactions (EDI) American Pharmaceutical Association, 2002
Gilman A.G., Rail T.W. Nies A.S., Taylor P. (eds). Goodman and Gilmans. The
Pharmacological basis of Therapeutics 10th ed., New York, Pergamon Press, 2001

18
7.

Hansten Ph. Important drug interactions and their mechanisms in: Basic & Clinical
Pharmacology, B.G.Katzung, eighth edition, Lange, 2001
8.
Jusko W.J. Role of tabacco smoking in pharmacokinetics. J. Pharmacokinetic. Biopharm.,
6:7, 1978
9.
May, E. Drug interactions and multiple drug administration. Clin. Pharmacol. Ther. 22: 322,
1977
10.
Prescott, L.F. Clinically important drug interactions In: Drug treatment. Ed.: Avery, G. 3rd
Ed. Adis Press, New York, pp. 255, 1987.
11.
Russell J. May. The Basics of Drug Interactions In: Pharmacotherapy. A Pathophysiologic
Approach. Elsevier Science Publishing Co., Inc. Chapter 7: 69, 1989.
12.
Smith D.C., Munoz C., Arnold M. et al. Grapefruit juice and naringin interaction with
nitrendipine. Clin. Pharmac. and Therap. 51: 156, 1992.
13.
Stockleys Drug Interactions, sixth edition, 2002
14.
Weinberger M.M., Smith G., Milavetz G. et al. Decreased theophylline clearance due to
cimetidine. N. Engl. J. Med., 304: 672, 1981.
15. The Medical Letter Handbook of Adverse Drug Interactions, Ed R.B. Kims and Editors of the
Medical Letter, Inc., New York, 2001
16. Managing Clinically Important Drug Interactions, Hansten Ph. D, Horn J. R, Facts and
Comparisons, 2002
17. .-:
, , 15, 4,
, . , 2003
18..-: ,2005